BIOYF Stock - BioSyent Inc.
Unlock GoAI Insights for BIOYF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $35.03M | $31.59M | $27.93M | $28.62M | $22.33M |
| Gross Profit | $27.86M | $25.60M | $22.86M | $22.64M | $17.42M |
| Gross Margin | 79.5% | 81.0% | 81.9% | 79.1% | 78.0% |
| Operating Income | $8.75M | $7.47M | $6.98M | $8.18M | $5.03M |
| Net Income | $7.27M | $6.46M | $5.46M | $6.28M | $3.80M |
| Net Margin | 20.8% | 20.4% | 19.5% | 21.9% | 17.0% |
| EPS | $0.64 | $0.53 | $0.44 | $0.50 | $0.29 |
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.
Visit WebsiteEarnings History & Surprises
BIOYFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | — | — | — | — |
Q4 2025 | Nov 20, 2025 | — | $0.17 | — | — |
Q3 2025 | Aug 21, 2025 | — | $0.13 | — | — |
Q2 2025 | May 15, 2025 | — | $0.14 | — | — |
Q1 2025 | Mar 11, 2025 | $0.10 | $0.10 | -8.8% | ✗ MISS |
Q4 2024 | Nov 20, 2024 | $0.10 | $0.15 | +42.8% | ✓ BEAT |
Q3 2024 | Aug 26, 2024 | $0.09 | $0.10 | +3.2% | ✓ BEAT |
Q2 2024 | May 16, 2024 | $0.06 | $0.11 | +85.7% | ✓ BEAT |
Q1 2024 | Mar 13, 2024 | $0.13 | $0.09 | -27.5% | ✗ MISS |
Q4 2023 | Nov 16, 2023 | $0.07 | $0.14 | +95.6% | ✓ BEAT |
Q3 2023 | Aug 22, 2023 | $0.09 | $0.09 | +0.7% | ✓ BEAT |
Q2 2023 | May 26, 2023 | $0.10 | $0.07 | -26.8% | ✗ MISS |
Q1 2023 | Mar 21, 2023 | $0.10 | $0.09 | -10.0% | ✗ MISS |
Q4 2022 | Nov 15, 2022 | $0.13 | $0.12 | -7.7% | ✗ MISS |
Q3 2022 | Aug 23, 2022 | $0.14 | $0.10 | -28.6% | ✗ MISS |
Q2 2022 | May 18, 2022 | $0.11 | $0.13 | +18.2% | ✓ BEAT |
Q1 2022 | Mar 8, 2022 | $0.11 | $0.15 | +36.4% | ✓ BEAT |
Q4 2021 | Nov 18, 2021 | $0.10 | $0.13 | +30.0% | ✓ BEAT |
Q3 2021 | Aug 25, 2021 | $0.10 | $0.08 | -20.0% | ✗ MISS |
Latest News
Frequently Asked Questions about BIOYF
What is BIOYF's current stock price?
What is the analyst price target for BIOYF?
What sector is BioSyent Inc. in?
What is BIOYF's market cap?
Does BIOYF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BIOYF for comparison